Cite
HARVARD Citation
He, J. et al. (2021). Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial. Lancet. 9 (9), pp. 1021-1029. [Online].